Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride may cause sleep disturbances, with some users experiencing insomnia. Reducing the dosage, switching brands, or trying Dutasteride might help.

RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.

Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.

Long-term use of finasteride and dutasteride may be linked to health risks like fatty liver disease, insulin resistance, type 2 diabetes, dry eye disease, and potential kidney disease. Some users believe the risks are low and the medications are generally safe.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.

The conversation discusses hair cloning trials expected to start in 2020-2021 and mentions concerns about potential delays due to the Coronavirus. Treatments like Minoxidil, finasteride, and RU58841 are referenced.

Dutasteride at 0.5mg may have fewer sexual side effects than expected, with many side effects attributed to psychological factors (nocebo effect). The placebo group experienced more side effects, suggesting fear and anxiety might contribute to perceived side effects.

Finasteride and minoxidil are praised for effectively treating hair loss, with users sharing positive experiences and some discussing side effects. Others express concerns about limited treatment options and the need for more research and alternatives.

Begin with finasteride to evaluate its effectiveness before adding minoxidil. Combining treatments may enhance results but could also increase side effects; individual responses differ.

Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.

The user wants to reduce their dose of topical finasteride to 0.1-0.2mg and is considering mixing 0.2ml of their current finasteride + minoxidil serum with 0.8ml of a minoxidil-only serum for better scalp coverage. They are asking for advice on whether this method is effective or if there's a better way to dilute the finasteride solution.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Elevated PGD2 levels in bald scalp tissue may contribute to hair loss, and treatments like castor oil, finasteride, and minoxidil are discussed as potential solutions. Some users explore alternatives like oral castor oil and cetirizine for those who cannot use finasteride.

A 30-year-old male experienced hair shedding while using Minoxidil and Finasteride, with concerns about whether this is a normal shedding phase. Despite drastic hair loss, he continues the treatment, hoping for regrowth, and receives advice to maintain the regimen and consider lifestyle changes.

People discussing hair loss treatments emphasize the need for patience, as results from using finasteride and minoxidil can take 8-12 months or longer. Some users report early signs of improvement, while others experience continued shedding or slower progress.

User sees subtle regrowth after two months using topical dutasteride, oral minoxidil, dermastamp, and oral castor oil. Others suggest waiting a few more months to properly evaluate results.

Finasteride users may have an increased risk of depression, anxiety, and suicidal thoughts, though some attribute these issues to hair loss itself. The link between finasteride and mental health effects is debated, with varying user experiences.

The trichologist recommended products with ingredients like retinol, caffeine, and placenta extract for AGA, but users believe these are ineffective and possibly a scam. They suggest consulting a dermatologist and using proven treatments like Minoxidil and Finasteride instead.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

The user shared progress pictures after using 5% topical minoxidil for two years and 1mg finasteride for one year, but many commenters believe the hair looks the same, attributing changes to different haircuts rather than actual regrowth. The user reported no side effects from finasteride, and opinions varied on whether any significant hairline improvement occurred.

Dutasteride may reduce bone mineral density, but there's no increased risk of osteoporosis or fractures compared to finasteride. Users suggest resistance training to counter potential bone effects.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

DHT negatively affects scalp hair while promoting body hair growth, causing frustration due to the lack of permanent solutions for baldness. Users discuss treatments like finasteride and potential future solutions like CRISPR technology.

The user has used oral Dutasteride and Minoxidil for two years without regrowth, despite trying Finasteride and supplements. They consider increasing Minoxidil, adding microneedling, and switching medications, while others suggest RU58841, a hair transplant, or checking for other hair loss causes.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Hair loss negatively affects mental health, causing anxiety and depression. Minoxidil and finasteride are discussed as treatments, but side effects and mental health concerns remain.

Concerns about a potential finasteride ban in the EU, possibly affecting the US, are discussed. Users doubt a ban, citing its widespread use and suggest alternatives like minoxidil and dutasteride.